AI-Based Skin Cancer Regenerative Treatment Successfully Conducted in Japan
Creatrip Team
a year ago
On July 3, Rokit Healthcare's stock saw a significant rise due to the successful announcement of AI-based skin cancer regenerative treatment clinical trials in Japan. The trials demonstrated that AI technology could fully regenerate skin tissue for elderly patients within four weeks, marking a revolutionary shift from traditional surgery methods towards regenerative-focused treatments. This breakthrough is seen as a game-changer in healthcare, especially for aging populations worldwide. The positive outcome opens doors for global commercialization in late 2023 across various regions including Japan, Korea, the USA, and Europe. Meanwhile, shares of GL PharmTech and Aptamer Sciences exhibited noticeable changes due to corporate actions and merger news.
